Australia markets closed
  • ALL ORDS

    7,726.80
    -1.70 (-0.02%)
     
  • ASX 200

    7,415.50
    +0.10 (+0.00%)
     
  • AUD/USD

    0.7468
    -0.0003 (-0.04%)
     
  • OIL

    83.98
    +1.48 (+1.79%)
     
  • GOLD

    1,793.10
    +11.20 (+0.63%)
     
  • BTC-AUD

    81,919.70
    -1,078.72 (-1.30%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • AUD/EUR

    0.6407
    -0.0015 (-0.23%)
     
  • AUD/NZD

    1.0428
    -0.0004 (-0.04%)
     
  • NZX 50

    13,093.24
    -32.74 (-0.25%)
     
  • NASDAQ

    15,355.07
    -134.52 (-0.87%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • Dow Jones

    35,677.02
    +73.94 (+0.21%)
     
  • DAX

    15,542.98
    +70.42 (+0.46%)
     
  • Hang Seng

    26,126.93
    +109.40 (+0.42%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     

Global Neurodiagnostics Market to Reach $9.3 Billion by 2027

·25-min read

Abstract: - Global Neurodiagnostics Market to Reach $9. 3 Billion by 2027. - Amid the COVID-19 crisis, the global market for Neurodiagnostics estimated at US$6. 1 Billion in the year 2020, is projected to reach a revised size of US$9.

New York, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neurodiagnostics Industry" - https://www.reportlinker.com/p06032331/?utm_source=GNW
3 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Diagnostic Imaging Systems, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Clinical Testing Instruments segment is readjusted to a revised 5.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 9.4% CAGR
- The Neurodiagnostics market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 9.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.
- Reagents & Consumables Segment to Record 5.8% CAGR
- In the global Reagents & Consumables segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$965.5 Million in the year 2020 will reach a projected size of US$1.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027, while Latin America will expand at a 7% CAGR through the analysis period.

- Select Competitors (Total 33 Featured) -

  • Advanced Brain Monitoring

  • ANT Neuro

  • Bio-Rad Laboratories

  • Canon, Inc.

  • DRG Instruments GmbH

  • Elmiko Medical Sp. Z o.o.

  • Fonar Corporation

  • Fujifilm Holdings Corporation

  • Fujirebio

  • GE Healthcare

  • Hitachi, Ltd.

  • Hoffman-La Roche AG

  • Lifelines Neuro Company, LLC

  • Mitsar Co., Ltd.

  • Motion Lab Systems, Inc.

  • Natus Medical Incorporated

  • Neusoft Medical Systems Co., Ltd.

  • Nihon Kohden Corporation

  • Philips Healthcare

  • Qiagen N.V.

  • Ridge Diagnostics

  • Rigaku Corporation

  • Siemens Healthineers

  • Tecan Trading AG

  • Thermo Fisher Scientific, Inc.




Read the full report: https://www.reportlinker.com/p06032331/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Neurodiagnostics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Neurodiagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Neurodiagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Diagnostic Imaging
Systems by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Diagnostic Imaging Systems
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Diagnostic Imaging
Systems by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 7: World Current & Future Analysis for Clinical Testing
Instruments by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Clinical Testing Instruments
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Clinical Testing
Instruments by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 10: World Current & Future Analysis for Reagents &
Consumables by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Reagents & Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Reagents & Consumables
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Hospitals &
Surgery Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Hospitals & Surgery Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Hospitals & Surgery
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Neurology Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Neurology Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Neurology Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Ambulatory Care
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Ambulatory Care Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Ambulatory Care Centers
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Neuro
Degenerative Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Neuro Degenerative Diseases
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Neuro Degenerative
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 28: World Current & Future Analysis for Epilepsy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Epilepsy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Epilepsy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Stroke by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Stroke by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Stroke by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Headache
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Headache Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Headache Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Sleep Disorders
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 38: World Historic Review for Sleep Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Sleep Disorders by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Other Conditions
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 41: World Historic Review for Other Conditions by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Other Conditions by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 43: USA Current & Future Analysis for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 44: USA Historic Review for Neurodiagnostics by Product -
Diagnostic Imaging Systems, Clinical Testing Instruments and
Reagents & Consumables Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: USA Historic Review for Neurodiagnostics by End-Use -
Hospitals & Surgery Centers, Neurology Centers, Ambulatory Care
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 48: USA 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: USA Historic Review for Neurodiagnostics by Condition -
Neuro Degenerative Diseases, Epilepsy, Stroke, Headache
Disorders, Sleep Disorders and Other Conditions Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: USA 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

CANADA
Table 52: Canada Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 53: Canada Historic Review for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 54: Canada 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: Canada Historic Review for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 58: Canada Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: Canada Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: Canada 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

JAPAN
Table 61: Japan Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 62: Japan Historic Review for Neurodiagnostics by Product -
Diagnostic Imaging Systems, Clinical Testing Instruments and
Reagents & Consumables Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 64: Japan Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: Japan Historic Review for Neurodiagnostics by End-Use -
Hospitals & Surgery Centers, Neurology Centers, Ambulatory
Care Centers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 66: Japan 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 67: Japan Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Japan Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

CHINA
Table 70: China Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 71: China Historic Review for Neurodiagnostics by Product -
Diagnostic Imaging Systems, Clinical Testing Instruments and
Reagents & Consumables Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 74: China Historic Review for Neurodiagnostics by End-Use -
Hospitals & Surgery Centers, Neurology Centers, Ambulatory
Care Centers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 75: China 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 76: China Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

EUROPE
Table 79: Europe Current & Future Analysis for Neurodiagnostics
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 80: Europe Historic Review for Neurodiagnostics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Neurodiagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 83: Europe Historic Review for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Europe 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 86: Europe Historic Review for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 88: Europe Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: Europe Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: Europe 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

FRANCE
Table 91: France Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 92: France Historic Review for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: France 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 94: France Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: France Historic Review for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 97: France Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: France Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: France 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

GERMANY
Table 100: Germany Current & Future Analysis for
Neurodiagnostics by Product - Diagnostic Imaging Systems,
Clinical Testing Instruments and Reagents & Consumables -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 102: Germany 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 103: Germany Current & Future Analysis for
Neurodiagnostics by End-Use - Hospitals & Surgery Centers,
Neurology Centers, Ambulatory Care Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 104: Germany Historic Review for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 106: Germany Current & Future Analysis for
Neurodiagnostics by Condition - Neuro Degenerative Diseases,
Epilepsy, Stroke, Headache Disorders, Sleep Disorders and Other
Conditions - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 107: Germany Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Germany 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

ITALY
Table 109: Italy Current & Future Analysis for Neurodiagnostics
by Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 110: Italy Historic Review for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 111: Italy 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 112: Italy Current & Future Analysis for Neurodiagnostics
by End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 113: Italy Historic Review for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 114: Italy 15-Year Perspective for Neurodiagnostics by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Surgery Centers, Neurology Centers, Ambulatory Care Centers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 115: Italy Current & Future Analysis for Neurodiagnostics
by Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 116: Italy Historic Review for Neurodiagnostics by
Condition - Neuro Degenerative Diseases, Epilepsy, Stroke,
Headache Disorders, Sleep Disorders and Other Conditions
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 117: Italy 15-Year Perspective for Neurodiagnostics by
Condition - Percentage Breakdown of Value Sales for Neuro
Degenerative Diseases, Epilepsy, Stroke, Headache Disorders,
Sleep Disorders and Other Conditions for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 118: UK Current & Future Analysis for Neurodiagnostics by
Product - Diagnostic Imaging Systems, Clinical Testing
Instruments and Reagents & Consumables - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 119: UK Historic Review for Neurodiagnostics by Product -
Diagnostic Imaging Systems, Clinical Testing Instruments and
Reagents & Consumables Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Neurodiagnostics by
Product - Percentage Breakdown of Value Sales for Diagnostic
Imaging Systems, Clinical Testing Instruments and Reagents &
Consumables for the Years 2012, 2020 & 2027

Table 121: UK Current & Future Analysis for Neurodiagnostics by
End-Use - Hospitals & Surgery Centers, Neurology Centers,
Ambulatory Care Centers and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 122: UK Historic Review for Neurodiagnostics by End-Use -
Hospitals & Surgery Centers, Neurology Centers, Ambulatory Care
Centers and Other End-Uses Markets - Independent Analysis of

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032331/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting